Trial Profile
A Long-term Follow up Study to Evaluate the Safety and Efficacy in Transplant Recipients Treated With Modified Release Tacrolimus, FK506E (MR4), Based Immunosuppression Regimen
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary)
- Indications Heart transplant rejection; Liver transplant rejection; Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Astellas Pharma Europe Ltd
- 30 Sep 2014 New trial record